Enliven Therapeutics, Inc. Common Stock

ELVNNASDAQUSD
53.38 USD
0.02 (0.03%)🟢PRE MARKET (AS OF 04:56 AM EDT)
🟢Market: OPEN

ELVN is currently priced at $53.38. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, ELVN trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Sep 15, 2026.

Open?$53.34
High?$53.38
Low?$53.34
Prev. Close?$53.36
Volume?N/A
Avg. Volume?965.3K
Bid / Ask
Bid?$46.35 × 100
Ask?$61.96 × 100
Spread?$15.61
Midpoint?$54.16
Valuation & Ratios
Market Cap?3.9B
Shares Out?73.3M
Float?60.8M
Float %?83.0%
P/E Ratio?N/A
P/B Ratio?4.37
EPS?-$1.45
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Employees
67
Market Cap
4.0B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2023-02-24
Address
205 PARK ROAD
BURLINGAME, CA 94010
Phone: 650-547-5814
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-1/3)
Medium-Term (Wave)? Bearish(-3/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
28
Piotroski F-Score?0/9Weak
Altman Z-Score?155.73Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?14.14%High
Short Interest?8.6M
Days to Cover?11.1
Free Float60.8M
Avg Daily Volume776.6K
Settlement Date2026-08-31
Financial Health
Current Ratio?64.07Strong
Quick Ratio?64.07Strong
Cash Ratio?9.57Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A
P/B?
Peers
100
S&P
41
4.37FAIR
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-30.4CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
9
-11.8%WEAK
ROA?
S&P
3
-11.6%WEAK
Cash Flow & Enterprise
FCF?$-67037000
Enterprise Value?$3.8B
Fundamentals ratios updated end of day